PMID- 24397553
OWN - NLM
STAT- MEDLINE
DCOM- 20141024
LR  - 20220328
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 15
IP  - 4
DP  - 2014 Mar
TI  - Agomelatine: a new option for treatment of depression?
PG  - 443-7
LID - 10.1517/14656566.2014.877889 [doi]
AB  - A number of diverse antidepressants with different mechanisms of action are 
      available today. However, the mechanisms of action of US FDA-approved 
      antidepressants still mainly rely on targeting monoamine neurotransmitters. The 
      inadequate remission and response rates achieved by antidepressant treatment for 
      depression have been well known through a number of manufacturer-sponsored 
      randomized, placebo-controlled, clinical trials (RCTs), independent RCTs, some 
      large practical clinical trials and many meta-analyses. In the light of the 
      limited efficacy of currently available antidepressants and the need for an 
      antidepressant with a novel mechanism of action, the availability of agomelatine 
      is prudent and timely for clinical practice. Although agomelatine has been 
      approved for the treatment of depression in Europe and some other countries, its 
      clear efficacy has been questionable based on results from individual RCTs and 
      meta-analyses. However, agomelatine may be more beneficial in specific 
      populations such as those who suffer from unwanted adverse events (AEs) (i.e., 
      sexual dysfunction) by current antidepressants or elderly populations who are 
      vulnerable to AEs. Based on currently available findings, agomelatine may not be 
      recommendable as the first-line antidepressant for treating depression; 
      especially, its putative benefits compared with other antidepressants must be 
      thoroughly studied in adequately powered and well-designed future clinical 
      trials.
FAU - Pae, Chi-Un
AU  - Pae CU
AD  - The Catholic University of Korea, College of Medicine, Department of Psychiatry , 
      Seoul , South Korea +82 32 340 7067 ; +82 32 340 2255 ; pae@catholic.ac.kr.
LA  - eng
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140108
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Acetamides)
RN  - 0 (Antidepressive Agents)
RN  - 137R1N49AD (agomelatine)
SB  - IM
MH  - Acetamides/*therapeutic use
MH  - Antidepressive Agents/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
EDAT- 2014/01/09 06:00
MHDA- 2014/10/25 06:00
CRDT- 2014/01/09 06:00
PHST- 2014/01/09 06:00 [entrez]
PHST- 2014/01/09 06:00 [pubmed]
PHST- 2014/10/25 06:00 [medline]
AID - 10.1517/14656566.2014.877889 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2014 Mar;15(4):443-7. doi: 
      10.1517/14656566.2014.877889. Epub 2014 Jan 8.